Audicin, a neurotechnology company, has raised $1.9 million in funding to further develop its real-time nervous system regulation solutions.
The round includes private investment, follow-on backing from Petteri Lahtela and Virpi Tuomivaara, as well as support from Business Finland through its Deep Tech Accelerator programme. The company’s total funding now stands at approximately $3 million, with the new capital aimed at advancing product development and commercialisation.
What The Company Does
Founded in 2022, Audicin develops technology that uses brainwave entrainment, auditory engineering, and music neuroscience to support focus, stress recovery, productivity, and sleep. Its core offering consists of adaptive audio sessions that respond to physiological signals, enabling continuous nervous system regulation throughout the day.
A central component of its platform is Audicin for Apps, a software development kit that allows developers to integrate real-time nervous system regulation into digital health, performance, and consumer applications. The system operates passively, triggered by inputs such as biometric data, time of day, or in-app events.
The platform integrates with wearable devices including Oura, Apple Watch, Garmin, and Whoop, allowing users to access its functionality without requiring additional hardware.
In parallel, the company is developing a standalone Sleep Headband designed for use in environments where connectivity may be restricted, such as healthcare and defence. The device delivers pre-configured audio-based recovery programmes linked to deep sleep phases.
Advertisement
Market Context / Industry Background
Interest in neurotechnology and digital health tools has increased as individuals and organisations seek solutions to manage stress, improve performance, and enhance recovery. Wearable devices and biometric tracking have enabled more personalised approaches to health, creating opportunities for technologies that can respond dynamically to user data.
At the same time, there is growing demand for passive and non-invasive solutions that can integrate into daily routines without requiring active user input. This has led to the emergence of systems that combine sensor data with adaptive outputs, particularly in areas such as sleep optimisation and cognitive performance.
Audicin’s approach reflects a broader trend toward embedding health-related interventions directly into digital environments and everyday workflows.
Founder / Investor Commentary
Laura Avonius, co-founder and CEO of Audicin, stated that the company is focused on integrating nervous system support into everyday environments. She emphasised the goal of enabling real-time regulation without requiring dedicated attention from users, particularly in contexts where maintaining performance and recovery is challenging.
Growth Plans / Use Of Funds
The newly raised funding will be used to support the commercialisation of Audicin’s core products, including its mobile application, Sleep Headband, and Audicin for Apps SDK.
The company also plans to expand its product capabilities and explore new use cases across sectors such as defence, performance, and wellness. Early traction includes growing enterprise interest and increasing user engagement following recent product updates.
About Audicin
Audicin is a neurotechnology company developing audio-based solutions to support nervous system regulation. Founded in 2022. Headquartered in Finland. The company provides tools designed to improve focus, relaxation, and sleep through adaptive sound experiences integrated with biometric data.
